MARAC Statement: ASH Report on Exercise and SCT Crisis Risk
Feb. 5, 2025 – On January 30, 2025, the American Society of Hematology (ASH) published a report that found no evidence... Continue Reading
Editas Medicine Announces Strategic Transition
Editas Medicine recently announced that they will be making a strategic transition to a in vivo gene editing company. The company... Continue Reading
SCDAA Statement on Recent Natural Disasters
SCDAA stands in solidarity with the warriors, advocates and community-based organizations who have been recently affected by natural disasters, including the... Continue Reading
In Memory of Frank Reddick
It is with great sadness that SCDAA shares the news of the passing of Frank Reddick on Dec. 23, 2024. Frank... Continue Reading
SCDAA Statement: CMS Cell and Gene Therapy Access Model
Nearly one year ago, the Food and Drug Administration (FDA) approved two new gene therapies for the treatment of sickle cell... Continue Reading
SCDAA names board officers
The Sickle Cell Disease Association of America Inc., a national nonprofit membership organization that advocates for people affected by sickle cell... Continue Reading
MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal 9/27/24 What is the news? Pfizer announced the withdrawal... Continue Reading
Sickle Cell Awareness Month 2024
All across the country, our member organizations are hosting exciting events for Sickle Cell Awareness Month this September. Check out the... Continue Reading
CHW P.O.W.E.R Award
CLICK HERE TO LEARN MORE AND MAKE A NOMINATION Do you know a community health worker who exemplifies excellence and commitment... Continue Reading
MARAC Statement: Parvovirus B19, Fever and Urgent Care
MARAC Statement: Parvovirus B19, Fever and Urgent Care Aug. 13, 2024 – More infections with parvovirus B19, also known as “fifth... Continue Reading